Keeping you up to date on recent developments in cardiology, including: Researchers outline new stroke strategy; Group assesses role of neutrophil extracellular traps in coronary thrombosis in COVID-19 patients; Link identified between metabolic syndrome and higher cardiovascular risk in patients with psoriasis.
A Chinese study has shown that the recently discovered transcription factor Bach2, which is important in B-cell development and progression of inflammatory disease, also regulates gastrointestinal regeneration by facilitating DNA repair after ionizing radiation exposure.
Keeping you up to date on recent developments in diagnostics, including: Arterial stiffness and mental decline; Wearables can help to predict COVID-19; Putting patients in control of type 2 diabetes with smart choices, CGMs.
Researchers at Duke University have developed a set of methods to separate out microbial contamination from microbiome species that were part of tumors and used those methods to gain new insights into tumor microbiomes.
Keeping you up to date on recent developments in orthopedics, including: What’s the ‘true’ rate of dislocation after total hip replacement?; A human gene placed in fruit flies reveals details about a human developmental disorder; Life expectancy and health care costs for patients with rheumatoid arthritis.
It has been a year since Wuhan health authorities first issued a bulletin about a cluster of pneumonia cases of unknown cause, first bringing what would become the COVID-19 pandemic to the attention of the World Health Organization. Now, a mutation that significantly increases SARS-CoV-2’s transmissibility has been detected in the U.S. On Dec. 29, Colorado public health authorities reported the first known case of infection with the SARS-CoV-2 VUI 202012/01 (Variant Under Investigation, year 2020, month 12, variant 01), also called B.1.1.7, variant in the U.S. The patient in question, a male in his 20s, has not traveled internationally, indicating that the variant is already circulating more widely in the U.S.
Scientists at Duke University School of Medicine in Durham, N.C., have developed a small-molecule inhibitor of the cellular stress-protective transcription factor, heat-shock factor 1, which showed developmental promise against treatment-resistant prostate cancer and other cancers. The small molecule, Direct Targeted HSF1 InhiBitor (DTHIB), may also be a useful research tool for investigating the regulation and role of HSF1 in basic stress biology and in cancer.
Keeping you up to date on recent developments in oncology, including: Microscopic robots inch closer to clinical practicability; One thing often leads to another for cancer patients; PARP inhibitors under more scrutiny; New liposome may suppress false positives in FDG-PET.
RSS
